Cardiovascular–Kidney–Metabolic (CKM) Syndrome Staging and Relevance to Precision Nutrition

Background/Objectives: It is estimated that one in three adults in the US has one or more risk factors for cardiovascular–kidney–metabolic (CKM) syndrome. The American Heart Association (AHA) has warned that the interaction between obesity, Type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease (CVD) leads to a multistage CKM syndrome with elevated mortality. This narrative review describes the newly coined terms CKM health and CKM syndrome, introduced by the AHA Presidential Advisory in 2023. Methods: In this narrative review, we will discuss the epidemiology and development of CKM syndrome, CKM stages, and the possible impact of precision nutrition on CKM and evaluate what is currently known about the role of nutrient metabolism in the physiological state and pathogenesis of CKM. Results: Since the AHA defined CKM syndrome in 2023, several studies have analyzed NHANES data to identify the correlations between CKM stages and adverse health outcomes. Studies also found that correlations between dietary intake and diet patterns may contribute to the protection against progression through various stages of CKM. However, experimental research and clinical studies are still lagging. Although the liver plays an integral role in nutrient metabolism, energy homeostasis, protein synthesis, nutrient storage, antibody production, and detoxifying compounds, it has not been included in the definition of CKM. Conclusions: Integrated body systems contribute to the development and progression of CKM. Precision nutrition and dietary patterns may play a role in the management of CKM and related comorbidities. Further research is warranted to address the role of precision nutrition in the prevention, early detection, and intervention in CKM syndrome as part of a comprehensive approach. It would be worth considering including metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) within the CKM framework.